Dr. V. Michael Holers of the University of Colorado has developed a method to prevent or treat ischemia-reperfusion injury in an individual by administering an agent that blocks or inhibits the binding of natural antibodies in the individual to annexin-4 and/or a phospholipid expressed on the surface of a cell that is in or adjacent to a tissue that is undergoing, or is at risk of undergoing, ischemia-reperfusion injury. These discoveries may be used to develop therapies that interrupt the inflammatory response at its earliest point by blocking natural antibody recognition of ischemia-induced targets. In this way, it may be capable of ameliorating inflammation caused by ischemia reperfusion injury in a variety of areas in critical care medicine, including myocardial infarction (over a million patients each year in the US), acute coronary syndrome (~1.5 million), ischemic stroke (600,000), sepsis (750,000) and kidney failure (400,000).
To read a non-confidential summary of this technology, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.
0 comments:
Post a Comment